Group 1 - The core viewpoint of the article highlights that CSPC Pharmaceutical Group (01093) has seen a stock price increase of approximately 9% year-to-date, with a notable rise of 14% prior to the announcement of its collaboration with AstraZeneca on January 30 [1] - HSBC Research has raised its revenue forecasts for CSPC for the years 2025 to 2027 by 3% to 11%, considering prepayments and slight improvements in sales from the previous quarter [1] - The net profit forecasts for CSPC for the years 2025 to 2027 have been increased by 7% to 18%, indicating that growth in external licensing revenue can offset the negative impacts of centralized procurement policies [1] Group 2 - Citi has indicated that the business development (BD) transactions completed by CSPC are expected to convert into recurring revenue starting this year [1] - CSPC's significant BD deals with AstraZeneca and Madrigal Pharmaceuticals are projected to generate approximately $10.2 billion in upfront and milestone payments, significantly boosting profits to 6.3 billion, 10.2 billion, and 10.9 billion RMB for the years 2025 to 2027 [1]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) has shown a year-to-date increase of approximately 9%, with a notable rise of 14% prior to the announcement of its collaboration with AstraZeneca on January 30. The valuation remains attractive, with expectations for more licensing opportunities in the EGFR ADC and R&D platforms [1] Group 1: Stock Performance and Valuation - CSPC's stock price increased by over 3%, currently trading at HKD 9.92, with a trading volume of HKD 378 million [1] - HSBC Research has raised revenue forecasts for CSPC for 2025 to 2027 by 3% to 11%, considering prepayments and slight improvements in last quarter sales [1] - The net profit forecast for 2025 to 2027 has been increased by 7% to 18%, indicating that growth in licensing revenue can offset negative impacts from centralized procurement policies [1] Group 2: Business Development and Future Earnings - Citi expects that completed business development (BD) transactions will start generating recurring revenue from this year [1] - CSPC has secured four significant BD transactions with AstraZeneca and Madrigal Pharmaceuticals, projected to yield approximately USD 10.2 billion in upfront and milestone payments, significantly boosting profits to RMB 6.3 billion, 10.2 billion, and 10.9 billion for 2025 to 2027 [1]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) has increased by approximately 9% year-to-date, with a notable rise of 14% prior to the announcement of its collaboration with AstraZeneca on January 30. HSBC Research maintains that the company's valuation remains attractive and anticipates more licensing opportunities in the future related to EGFR ADC and its R&D platform [1][1][1] Group 1 - HSBC has raised its revenue forecasts for CSPC Pharmaceutical Group for 2025 to 2027 by 3% to 11%, considering prepayments and slight improvements in last quarter sales [1][1][1] - The net profit forecasts for the same period have been increased by 7% to 18%, indicating that growth in licensing revenue can offset the negative impacts of centralized procurement policies for pharmaceuticals [1][1][1] Group 2 - Citi expects that the business development (BD) transactions already completed by CSPC will start converting into recurring revenue from this year [1][1][1] - The four significant BD transactions with AstraZeneca and Madrigal Pharmaceuticals are projected to generate approximately $10.2 billion in upfront and milestone payments, significantly boosting profits to 6.3 billion, 10.2 billion, and 10.9 billion RMB for 2025 to 2027 [1][1][1]

这一独特的合作架构也为信达生物打造了全新的合作模式，加速公司创新研发管线的全球化开发进程。 根据合 【信达生物】更新：与礼来达成全球战略合作，驱动创新加速与价值兑现 事件：2026年2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。 本次协议为双方第七次合作，进一步深化了双方长期且富有成效的合作伙伴关系，携手为全球患者带来创新药 物。 【信达生物】更新：与礼来达成全球战略合作，驱动创新加速与价值兑现 事件：2026年2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。 本次协议为双方第七次合作，进一步深化了双方长期且富有成效的合作伙伴关系，携手为全球患者带来创新药 物。 合作看点2：信达生物的核心竞争力在于成熟的抗体技术平台和高效的临床研发能力，在本次合作中被反复强调， 作为主导早期研发的基础。 1）抗体技术平台：成熟的全人抗体发现平台，支持单抗、双抗、三抗、ADC、融合蛋白等。 这一独特的合作架构也为信达生物打造了全新的合作模式，加速公司创新研发管线的全球化开发进程。 根据合作协议，双方将发挥互补优势，加快推进创新药物的全球研发工作。 ...

Group 1 - The core viewpoint of the article is that Innovent Biologics (1801.HK) has entered a strategic collaboration with Eli Lilly to advance the global development of innovative drugs in oncology and immunology [1] - Innovent Biologics experienced a nearly 9% increase in stock price, reaching HKD 86.3 at the beginning of trading [1] - According to the agreement, Innovent will receive an upfront payment of USD 350 million (approximately HKD 2.73 billion) [1] Group 2 - The collaboration includes potential milestone payments totaling up to USD 8.5 billion (approximately HKD 66.3 billion) based on the achievement of specific development, regulatory, and commercialization milestones [1] - Innovent will also have the right to receive a tiered sales share from the net sales of each product outside of Greater China [1]

Group 1 - The Hong Kong stock market showed a strong opening on February 9, with the Hang Seng Index rising by 1.59%, the State-owned Enterprises Index increasing by 1.54%, and the Technology Index up by 1.9% [1] - The Hang Seng Biotechnology Index, focusing on innovative drugs, performed robustly, with the largest ETF tracking this index (159892) rising nearly 2% [1] - The innovative drug sector is expected to enter a profit realization acceleration phase by 2025, with companies like Innovent Biologics and Rongchang Biopharmaceuticals turning losses into profits, while companies like 3SBio are significantly increasing their performance [1] Group 2 - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product volume growth supported by medical insurance becoming the foundation for performance growth [1] - External collaborations, such as business development (BD) partnerships, are becoming important drivers for enhancing performance in the innovative drug sector [1] - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, covering numerous innovative targets like BeiGene and Innovent Biologics, and is expected to continue its valuation recovery trend under catalysts like overseas expansion of innovative drugs and commercial insurance directories [1]

Group 1 - Morgan Stanley reduced its holdings in WuXi AppTec (02359.HK) by approximately 798,119 shares at a price of HKD 109.1481 per share, totaling around HKD 87.1132 million [1][2] - After the reduction, Morgan Stanley's remaining shares amount to approximately 35,245,132, representing a holding percentage of 6.90% [1][2] - The previous day, February 2, Morgan Stanley had increased its holdings by 1,490,412 shares at an average price of HKD 109.281, resulting in a holding percentage of 7.06% before the reduction [2]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based more on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry average this year will rely more on key data releases, actual transactions, and visibility on profit realization or turning points [1] Group 2: Sector Analysis - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing some promise, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Innovent Biologics, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector maintains a neutral outlook, as the industry has bottomed out but requires time for gradual recovery [1] - Recommendations include buying Angelalign Technology and Weigao Group [1]

Core Viewpoint - Gilead Sciences-B (01672) shares rose nearly 9% in early trading, with a current price of HKD 16.45 and a trading volume of HKD 42.25 million, following a significant investment from the Government of Singapore Investment Corporation (GIC) [1][5]. Group 1 - GIC purchased approximately 64.12 million new shares of Gilead Sciences at an average price of HKD 12.18 per share, totaling around HKD 781 million, resulting in GIC holding a 6.42% stake in the company [1][5]. - The investment is part of Gilead Sciences' recent completion of a placement plan, where the company sold a total of 69.26 million shares, raising a net amount of approximately HKD 835 million [1][5]. - Gilead Sciences indicated that 90% of the funds raised will be allocated for the global Phase III clinical development of the oral small molecule GLP-1 receptor agonist ASC30, covering trial preparation, foundational work, and formal initiation; the remaining 10% will be used for operational funding [1][5].

Market Overview - The A-share market showed a decline on February 6, with the Shanghai Composite Index down 0.25% to 4,065.58 points, the Shenzhen Component Index down 0.33% to 13,906.73 points, and the ChiNext Index down 0.73% to 3,236.46 points [11] - In the Asia-Pacific market, the Hang Seng Index fell 1.21% to 26,559.95 points, while the Nikkei 225 rose 0.81% to 54,253.68 points [11] - The US stock market saw all three major indices rise, with the Dow Jones up 2.47% to 50,115.67 points, marking a new closing high above 50,000 points [11] International News - The US has initiated a new round of sanctions against Iran, imposing additional tariffs on goods from countries trading with Iran, which has led to rising oil prices following US-Iran talks [9] - France's exports to the US have significantly declined, with a 13% year-on-year drop in the fourth quarter of 2025, particularly in sectors like spirits and wine [10] Domestic News - The Chinese government has issued regulatory guidelines for the issuance of overseas asset-backed securities tokens, aiming to mitigate risks associated with virtual currency trading [12] - Premier Li Qiang emphasized the importance of strengthening domestic circulation and planning for high-quality development in various sectors during a State Council meeting [13] Important Announcements - Meituan plans to acquire 100% of Dingdong Maicai's China business for approximately $717 million, which has positively impacted Dingdong's stock price [14] - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [15] - Suning Holdings' controlling shareholder will change to Anhui State-owned Assets Supervision and Administration Commission following a restructuring agreement [15]